切换至 "中华医学电子期刊资源库"
高级检索
中华肺部疾病杂志(电子版)

中华肺部疾病杂志(电子版) ›› 2020, Vol. 13 ›› Issue (01) : 34 -38. doi: 10.3877/cma.j.issn.1674-6902.2020.01.007

论著

JDP2、Phf2蛋白在非小细胞肺癌组织中的表达及其与病理特征的相关性
彭凤翔1,†(), 李丹2, 高蓉梅1, 李永春1, 叶小娟1   
  1. 1. 614000　乐山，武警四川省总队医院病理科
    2. 400016　重庆，重庆医科大学基础医学院病理学教研室
  • 收稿日期:2019-09-18 出版日期:2020-02-25
  • 通信作者: 彭凤翔
  • 基金资助:
    国家重点研发计划(2016YFC1307200)

Expression levels of Jun dimerization protein and Phf2 in patients with non-small cell lung cancer and their correlation with pathological features

Fengxiang Peng1,†(), Dan Li2, Rongmei Gao1, Yongchun Li1, Xiaojuan Ye1   

  1. 1. Department of Pathology, Sichuan Provincial Armed Police Corps Hospital, Leshan 614000, Sichuan Province, China
    2. Department of Pathology, Faculty of Basic Medical Science, Chongqing Medical University, Chongqing 400016, China
  • Received:2019-09-18 Published:2020-02-25
  • Corresponding author: Fengxiang Peng
全文 ( ) 下载PDF ( ) 导出引用
引用本文：

彭凤翔, 李丹, 高蓉梅, 李永春, 叶小娟. JDP2、Phf2蛋白在非小细胞肺癌组织中的表达及其与病理特征的相关性[J]. 中华肺部疾病杂志(电子版), 2020, 13(01): 34-38.

Fengxiang Peng, Dan Li, Rongmei Gao, Yongchun Li, Xiaojuan Ye. Expression levels of Jun dimerization protein and Phf2 in patients with non-small cell lung cancer and their correlation with pathological features[J]. Chinese Journal of Lung Diseases(Electronic Edition), 2020, 13(01): 34-38.

目的

探讨二聚化蛋白(JDP2)、Phf2蛋白在非小细胞肺癌(NSCLC)组织中的表达水平，及其与病理特征相关性。

方法

收集2018年1月至2019年3月我院切除并经病理证实的65例NSCLC标本，其中>肿瘤边缘5 cm的癌旁组织作为空白对照组，收集患者基线资料性别、年龄、BMI、肿瘤直径、分化程度、肿瘤转移、肿瘤分期、病理类型及三年生存情况，采用免疫组化染色法检测JDP2、Phf2蛋白表达量，分析JDP2、Phf2蛋白与NSCLC患者临床病理特征及预后生存期相关性。

结果

癌旁组织中JDP2、Phf2阳性表达率高于癌组织中JDP2、Phf2阳性表达率(P<0.05)。采用Spearman值分析两者关联性，结果JDP2、Phf2在NSCLC组织中共同表达呈负相关关系，二者具有协同作用(P<0.05)。分期Ⅲ期、出现肿瘤转移的NSCLC患者JDP2、Phf2阳性表达率低于分期Ⅰ/Ⅱ期、无肿瘤转移NSCLC患者JDP2、Phf2阳性表达率，而分化程度高级的NSCLC患者JDP2、Phf2阳性表达率高于分化程度低级的NSCLC患者JDP2、Phf2阳性表达率(P<0.05)。3年随访期间存活患者42例(64.62%)，死亡23例(35.38%)。肿瘤直径>3 cm、TNM分期Ⅲ期、出现肿瘤转移、JDP2阴性、Phf2阴性的NSCLC患者存活率低于肿瘤直径≤3 cm、TNM分期Ⅰ/Ⅱ期、无肿瘤转移、JDP2阳性、Phf2阳性的NSCLC患者(P<0.05)。

结论

JDP2、Phf2蛋白在NSCLC组织中均呈低表达，其表达水平与患者肿瘤TNM分期、肿瘤转移及预后呈相关性。

关键词: 二聚化蛋白, Phf2, 非小细胞肺癌, 表达, 病理特征, 相关性
Objective

To investigate the expression levels of Jun dimerization protein (JDP2) and Phf2 in the patients with non-small cell lung cancer (NSCLC) and to analyze their correlation with the pathological characteristics.

Methods

A total of 65 NSCLC specimens and the adjacent normal tissues of cancer collected from the pathologically-confirmed patients in our hospital from January 2018 to March 2019 were enrolled for this study. The baseline data including gender, age, BMI, tumor diameter, degree of differentiation, tumor metastasis, tumor stage, pathological type and three-year survival rate were collected. The expression levels of JDP2 and phf2 were detected by immunohistochemistry, and their correlation with the clinicopathological characteristics and the prognosis of NSCLC patients was analyzed.

Results

The positive expression rates of JDP2 and Phf2 in the adjacent normal tissues of cancer were higher than those of the cancer tissues (P<0.05). Spearman analysis showed that the expression levels of JDP2 and Phf2 in the NSCLC tissues were negatively correlated, and they had a synergistic effect (P<0.05). The positive expression rates of JDP2 and Phf2 in the NSCLC patients at Stage Ⅲ and with tumor metastasis were lower than those of the patients in Stage Ⅰ/Ⅱ and without tumor metastasis. Moreover, the positive expression rates of JDP2 and Phf2 in the patients with advanced differentiation of NSCLC were higher than those of the patients with low differentiation degree (P<0.05). During the 3-year follow-up period, 42 patients (64.62%) survived and 23 patients died (35.38%). The survival rates of the NSCLC patients with tumor diameter>3 cm, TNM stage Ⅲ, tumor metastasis, negative JDP2 and negative Phf2 were lower than the NSCLC patients with tumor diameter ≤3 cm, TNM stage Ⅰ/Ⅱ, no tumor metastasis, positive JDP2 and positive Phf2 (P<0.05).

Conclusion

The expression levels of JDP2 and Phf2 are lower in the NSCLC tissues and their expression levels are correlated with the tumor TNM stage, tumor metastasis and prognosis, which may provide a reference for early diagnosis and prognosis evaluation of the NSCLC patients.

Key words: Jun dimerization protein, Phf2, Non-small cell lung cancer, Expression, Pathological features, Correlation
图1 JDP2在癌旁组织(左)和癌组织(右)中的表达
图2 Phf2在癌旁组织(左)和癌组织(右)中的表达
表1 JDP2、Phf2阳性表达率(n)
项　目 例数 + 构成比(%) - 构成比(%) χ2值 P值
JDP2           29.823 <0.001
癌旁组织 65 51 78.46 14 21.54    
癌组织 65 20 30.77 45 69.23    
Phf2           44.695 <0.001
癌旁组织 65 54 83.08 11 16.92    
癌组织 65 16 24.62 49 75.38    
表2 JDP2、Phf2与NSCLC患者临床病理特征的关系(n)
临床资料 例数 JDP2 χ2值 P值 Phf2 χ2值 P值
+ - + -
年龄/岁       3.552 0.060     3.010 0.083
  ≤60岁 24 4 20     3 21    
  >60岁 41 16 25     13 28    
性别       1.204 0.273     0.677 0.411
  男 39 14 25     11 28    
  女 26 6 20     5 21    
BMI/kg·m-2       3.850 0.050     0.269 0.604
  ≤21.32 37 15 22     10 27    
  >21.32 28 5 23     6 22    
肿瘤直径/cm       0.985 0.321   1.169 0.280  
  ≤3 33 12 21     10 23    
  >3 32 8 24     6 26    
分级程度       12.341 0.002     8.652 0.013
  低级 26 3 23     4 22    
  中级 21 6 15     3 18    
  高级 18 11 7     9 9    
肿瘤TNM分期       9.820 0.007     9.052 0.011
  Ⅰ期 22 11 11     9 13    
  Ⅱ期 19 7 12     6 13    
  Ⅲ期 24 2 22     1 23    
肿瘤转移       7.675 0.006     12.437 <0.001
  无 32 15 17     14 18    
  有 33 5 28     2 31    
病理类型       0.028 0.867     0.143 0.706
  腺癌 27 8 19     6 21    
  鳞癌 38 12 26     10 28    
表3 随访期间生存结果比较(n)
病理参数 类型 例数 存活 构成比(%) 死亡 构成比(%)
肿瘤直径/cm ≤3 33 26 78.79 7 21.21
  >3a 32 16 50.00 16 50.00
分级程度 低级 26 17 65.38 9 34.62
  中级 21 14 66.67 7 33.33
  高级 18 11 61.11 7 38.89
肿瘤TNM分期 Ⅰ期 22 20 90.91 2 9.09
  Ⅱ期 19 12 63.16 7 36.84
  Ⅲ期a 24 10 41.67 14 58.33
肿瘤转移 无 32 28 87.50 4 12.50
  有a 33 14 42.42 19 57.58
JDP2 + 20 16 80.00 4 20.00
  -a 45 26 57.78 19 42.22
Phf2 + 16 14 87.50 2 12.50
  -a 49 28 57.14 21 42.86
1
刘天艺. Oct4 mRNA在非小细胞肺癌患者肿瘤组织的表达与病理特征的相关性分析[J/CD]. 中华肺部疾病杂志(电子版), 2019, 12(3): 342-344.
2
Mao WX, Han W. The correlation of contrast-enhanced CT quantitative parameters with proliferation and invasion gene expression in pancreatic cancer[J]. J Hainan Medical University, 2017, 23(2): 139-142.
3
Cheol L, Bohyun K, Boram S, et al. Implication of PHF2 Expression in Clear Cell Renal Cell Carcinoma[J]. J Pathol Transl Med, 2017, 51(4): 359-364.
4
Rice TW, Ishwaran H, Hofstetter WL, et al. Esophageal cancer: associations with (pN+) lymph node metastases[J]. Annals of Surgery, 2017, 265(1): 122-129.
5
Park JH, Jung M, Moon KC. The prognostic significance of nuclear expression of PHF2 and C/EBPα in clear cell renal cell carcinoma with consideration of adipogenic metabolic evolution[J]. Oncotarget, 2018, 9(1): 142-151.
6
崔　巍，王硕仁，朱陵群，等. 平均光密度值分析法和阳性染色面积分析法在免疫组化图像分析中的对比研究[C]//2008中华中医药学会内科分会中医内科学科建设研讨会论文汇编. 2008: 23-27.
7
Jin C, Kato K, Chimura T, et al. Regulation of histone acetylation and nucleosome assembly by transcription factor JDP2[J]. Nat Struct Mol Biol, 2016, 13(4): 331-338.
8
Kalfon R, Haas T, Shofti R, et al. c-Jun dimerization protein 2 (JDP2) deficiency promotes cardiac hypertrophy and dysfunction in response to pressure overload[J]. Int J Cardiol, 2017, 10(249): 357-363.
9
张裔麒元，王佳宁，周　昱. lncRNA XIST通过调控miR-1269b/SOX6抑制乳腺癌生长、迁移和侵袭的研究[J]. 国际免疫学杂志，2019, 42(4): 358-364.
10
Murata T, Noda C, Saito S, et al. Involvement of Jun Dimerization Protein 2 (JDP2) in the Maintenance of Epstein-Barr Virus Latency[J]. J Biol Chem, 286(25): 22007-22016.
11
李晓波，吴　波，曾　义，等. EDNRA和JDP2基因与中国汉族人群散发颅内动脉瘤关联分析[J]. 中华神经医学杂志，2014, 13(4): 383-387.
12
Zhang Y, Hu W, Wang L, et al. Association of GOLPH2 expression with survival in non-small-cell lung cancer: clinical implications and biological validation[J]. Biomark Me, 2017, 11(2): 967-977.
13
李佳浓，于冠宇，郑　阔. PHF1基因在不同类型非小细胞肺癌中的表达水平及其生物学功能[J]. 热带医学杂志，2019, 19(3): 320-324.
14
Zheng G, Yan G, Qi H. Plant homeodomain finger protein 2 as a novel IKAROS target in acute lymphoblastic leukemia[J]. Epigenomics, 2018, 10(1): 59-69.
15
Jeong HP, Minsun J, Kyung CM. The prognostic significance of nuclear expression of PHF2 and C/EBPα in clear cell renal cell carcinoma with consideration of adipogenic metabolic evolution[J]. Oncotarget, 2018, 9(1): 142-151.
16
孙翠翠，张斯萌，温　倜，等. 晚期非小细胞肺癌肿瘤生长速率与临床病理特征及预后的相关性[J]. 中国医科大学学报，2019, 48(8): 673-677.
17
刘　谦. Ki-67、Geminin、H3S10ph在非小细胞肺癌中的表达及其预后意义[D]. 南昌大学，2012: 12-24.
18
Fang J, Ying L, Zhang J. Correlation between polymorphisms in microRNA-regulated genes and cervical cancer susceptibility in a Xinjiang Uygur population[J]. Oncotarget, 2017, 8(19): 31758-31764.
19
刘　辉，王晓彬，贾招辉，等. 膀胱癌患者外周血中髓系来源的抑制细胞与肿瘤分期的关系[J]. 中华实验外科杂志，2018, 35(9): 1653-1655.
20
郑二良，吴清彬，邓祥兵，等. 结合CT影像学及临床病理学特征评估直肠癌术前N分期[J]. 中华结直肠疾病电子杂志，2018, 7(3): 218-222.
21
Yang J, Ma J, Xiong Y, et al. Epigenetic regulation of megakaryocytic and erythroid differentiation by PHF2 histone demethylase: PHF2 negatively regulates megakaryocytic and erythroid differentiation[J]. J Cell Physiol, 2018, 233(9): 6841-6852.
22
Nakade K, Lin CS, Chen XY, et al. Jun dimerization protein 2 controls hypoxia-induced replicative senescence via both the p16Ink4a-pRb and Arf-p53 pathways[J]. FEBS Open Bio, 2017, 7(11): 1793-1804.
23
Li HS, Lv RQ, Liu L. Correlation of CT indicators of NSCLC and pathological features and the expression level of p53 and c-myc[J]. Eur Rev Med Pharmacol Sci, 2018, 22(1): 135-137.
24
刘佳勋，夏建宇，於建鹏. Fibulin-1基因表达与肾细胞癌的关系研究[J]. 国际泌尿系统杂志，2017, 37(4): 512-514.
25
Amin AK. Ox-LDL-induced Histone Demethylase PHF2, Contributes to the Inflammatory Cytokines, Expression via An Epigenetic Mechanism[J]. J Arteriosclerosis, 2016, 21(9): I0077-I00779.
26
Goss G, Tsai CM, Shepherd FA, et al. CNS response to osimertinib in patients with T790M-positive advanced NSCLC: pooled data from two Phase Ⅱ trials[J]. Ann Oncol, 2017, 29(3): S440-S441.
[1] 王培蕾, 夏罕生, 俞清, 闻捷先, 黄备建. IgG4相关性乳腺炎多模态影像学表现及其治疗转归一例[J]. 中华乳腺病杂志(电子版), 2024, 18(04): 244-247.
[2] 李世杰, 申传安. 烧伤合并吸入性损伤患者呼吸机相关肺炎的研究现状[J]. 中华损伤与修复杂志(电子版), 2024, 19(04): 351-355.
[3] 李雪, 韩萌萌, 冯雪园, 马宁. 人表皮生长因子受体2低表达乳腺癌的研究进展及挑战[J]. 中华普通外科学文献(电子版), 2024, 18(04): 308-312.
[4] 孙建娜, 孔令军, 任崇禧, 穆坤, 王晓蕊. 266例首诊Ⅳ期乳腺癌手术患者预后分析[J]. 中华普外科手术学杂志(电子版), 2024, 18(05): 502-505.
[5] 蔡大明, 陆晓峰, 王行舟, 王萌, 刘颂, 夏雪峰, 沈晓菲, 杜峻峰, 管文贤. 三级淋巴结构在胃神经内分泌瘤中的预后价值及预后预测模型构建[J]. 中华普外科手术学杂志(电子版), 2024, 18(04): 401-405.
[6] 赵蒙蒙, 黄洁, 余荣环, 王葆青. 过表达小GTP酶Rab32抑制非小细胞肺癌细胞侵袭性生长[J]. 中华肺部疾病杂志(电子版), 2024, 17(04): 512-518.
[7] 张桂萍, 丘勇林, 湛绮婷, 孙乐栋. 晚期非小细胞肺癌血清Ape1/Ref-1对放射性肺损伤发生的预测意义[J]. 中华肺部疾病杂志(电子版), 2024, 17(04): 519-523.
[8] 韩晓宇, 李柯育, 赵志菲, 高建平. SNHG17过表达对非小细胞肺癌切除术预后的意义[J]. 中华肺部疾病杂志(电子版), 2024, 17(04): 543-547.
[9] 刘松, 张进召, 贾艳云. 帕博利珠单抗治疗晚期非小细胞肺癌反应降低与抗生素预处理的关系[J]. 中华肺部疾病杂志(电子版), 2024, 17(04): 553-557.
[10] 李多, 郝昭昭, 陈延伟, 南岩东. 血清PTX3表达与非小细胞肺癌骨转移的相关性分析[J]. 中华肺部疾病杂志(电子版), 2024, 17(04): 558-562.
[11] 燕红玲, 王岩岩, 陈树斌. PCT、NLR联合LUBS预测ICU CRKP致呼吸机相关肺炎撤机及预后分析[J]. 中华肺部疾病杂志(电子版), 2024, 17(04): 617-620.
[12] 罗道首, 陈树林, 李向东, 李小荣, 柯赛, 崔文志, 何小华. 大细胞肺癌患者的影像学特点及病理临床特征分析[J]. 中华肺部疾病杂志(电子版), 2024, 17(04): 642-644.
[13] 张怡, 王宇洋, 司梦娇, 曹燕, 李欢欢. 脑卒中前白蛋白与肺炎发生风险相关性分析[J]. 中华肺部疾病杂志(电子版), 2024, 17(04): 648-651.
[14] 甘曦, 廖鑫. 胃癌旁肿瘤沉积与CT影像学特征、血清指标及病理特征的关联性分析[J]. 中华消化病与影像杂志(电子版), 2024, 14(05): 422-425.
[15] 唐小久, 胡曼, 许必君, 肖亚. 肥胖合并胃食管反流病患者严重程度与其焦虑抑郁及营养状态的相关性研究[J]. 中华消化病与影像杂志(电子版), 2024, 14(04): 360-364.
阅读次数
全文


摘要

版权所有 中华医学会 中华医学电子音像出版社有限责任公司  京ICP备14006079号-1  网络出版服务许可证：(署)网出证(京)字第075号